RT Journal Article SR Electronic T1 99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 716 OP 722 DO 10.2967/jnumed.111.098988 VO 53 IS 5 A1 Zhaohui Zhu A1 Weibing Miao A1 Qianwei Li A1 Haojie Dai A1 Qingjie Ma A1 Feng Wang A1 Aiming Yang A1 Bing Jia A1 Xiaona Jing A1 Sha Liu A1 Jiyun Shi A1 Zhaofei Liu A1 Zhoushe Zhao A1 Fan Wang A1 Fang Li YR 2012 UL http://jnm.snmjournals.org/content/53/5/716.abstract AB 99mTc-3PRGD2 is a new SPECT tracer targeting integrin αVβ3 receptor for detecting tumors, imaging angiogenesis, and evaluating tumor response to therapy. A multicenter study was designed to investigate the efficacy of 99mTc-3PRGD2 for the evaluation of patients with lung cancer. Methods: Seventy patients (51 men, 19 women; mean age ± SD, 63 ± 9 y) with a suspected lung lesion and for whom definite pathologic diagnosis was finally obtained (malignant, n = 58; benign, n = 12) were recruited from 6 centers. Whole-body planar scanning and chest SPECT were performed at 1 and 4 h, respectively, after intravenous injection of 11.1 MBq/kg (0.3 mCi/kg) of 99mTc-3PRGD2. The images were read in consensus by 6 experienced nuclear medicine physicians masked to the source, history, and pathologic diagnosis. The tumor-to-background (T/B) ratios were calculated for semiquantitative analysis. A Student t test was used for statistical analysis, and a P value less than 0.05 was considered significant. Results: With low 99mTc-3PRGD2 background in the lungs and mediastinum, most lung malignancies were prominent on the 1-h images (T/B ratio, 1.65 ± 0.47 for the planar imaging and 2.78 ± 1.52 for SPECT). The T/B ratios were significantly lower in the benign lesions (P < 0.05). The sensitivity was 88% for semiquantitative analysis and could reach 93%–97% in visual analysis when considering the volume effect, necrosis, and metastasis. However, the specificity was only 58%–67%. Most lymph node and bone metastases could also be detected. Conclusion: 99mTc-3PRGD2 imaging at 1 h is sensitive for the detection of lung cancer, meriting further investigation of 99mTc-3PRGD2 as a novel clinical tracer for integrin receptor imaging.